Navigation Links
Cadence Pharmaceuticals Appoints Laureen DeBuono to its Board of Directors
Date:8/15/2013

SAN DIEGO, Aug. 15, 2013 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, announced today the appointment of Laureen DeBuono to the company's board of directors.  Ms. DeBuono will also serve as a member of the company's audit committee.

"We are very pleased to welcome Ms. DeBuono to Cadence's board of directors," stated Cam Garner, Chairman of Cadence. "Laureen has a wealth of experience in senior leadership positions with several private and public life sciences, medical technology and consumer products companies. We believe that her extensive background in developing and executing complex corporate and financial strategies will make her an important addition to our board, as we continue to explore opportunities to add new products to our portfolio for use within the hospital setting."

Ms. DeBuono has been a partner of FLG Partners, LLC, a leading CFO consulting services firm, since October 2011.  Prior to joining FLG Partners, Ms. DeBuono served as President, CEO and member of the board of directors of Coapt Systems, Inc., and as Chief Financial Officer of Thermage, Inc. Previously, Ms. DeBuono served as consulting chief financial officer, executive vice president, chief operations officer and general counsel of several medical technology, consumer products, and technology companies. Ms. DeBuono is currently a member of the board of directors of two privately-held companies, Cradle Holdings, Inc., and VenX LLC.  She previously served as a member of the board of directors and audit committee chair of two public companies, VISX, Inc. and InVivo Medical Diagnostics, Inc., and as a member of the b
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Cadence Pharmaceuticals To Present At The 2013 Wedbush PacGrow Life Sciences Management Access Conference On August 13, 2013
2. Cadence Pharmaceuticals Reports Second Quarter 2013 Financial Results
3. Cadence Pharmaceuticals To Host Conference Call And Webcast To Discuss Second Quarter 2013 Financial Results On July 31, 2013
4. Cadence Pharmaceuticals To Present At Three Investment Conferences During The Month Of May 2013
5. Cadence Pharmaceuticals To Host Conference Call And Webcast To Discuss First Quarter 2013 Financial Results On May 2, 2013
6. Cadence Pharmaceuticals Appoints Stephen L. Newman, M.D., to its Board of Directors
7. Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2012 Financial Results
8. Cadence Pharmaceuticals To Host Conference Call And Webcast To Discuss Fourth Quarter And Full Year 2012 Financial Results On March 7, 2013
9. Cadence Pharmaceuticals CEO Ted Schroeder To Present At The Cowen & Company 33rd Annual Health Care Conference In Boston On March 5, 2013
10. Cadence Pharmaceuticals CEO Ted Schroeder To Present At The Leerink Swann Global Healthcare Conference In New York City On February 13, 2013
11. Cadence Pharmaceuticals Estimates Fourth Quarter 2012 Net Product Revenue and Provides Full Year 2013 Revenue Guidance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... July 31, 2014   Auxilium Pharmaceuticals , Inc. ... biopharmaceutical company, today announced that the Company will release ... August 7, 2014 before the opening of the U.S. ... call that day at 8:30 a.m. ET to discuss ... The presentation slides to be used during the call ...
(Date:7/31/2014)... , July 31, 2014  A substantial share ... decisions about which therapies are included in formularies—say ... according to a new Manhattan Research study, ... The study finds that P&T committee members in ... managers (PBMs) have set a high bar for ...
(Date:7/31/2014)... Catylix, Inc. ( Burbank, California ... California ) announced today the formation of ... fluorination products and related chemistry. Developing ... use of substituents that are chemically stable, resistant ... improve binding and bioavailability. Fluorinated functional groups are ...
Breaking Medicine Technology:Auxilium Pharmaceuticals, Inc. To Announce Second Quarter 2014 Results On August 7, 2014 2Auxilium Pharmaceuticals, Inc. To Announce Second Quarter 2014 Results On August 7, 2014 3Formulary Decision Makers Say Pharma-Provided Patient Support Solutions Influence Formulary Placement 2Formulary Decision Makers Say Pharma-Provided Patient Support Solutions Influence Formulary Placement 3Catylix, Inc. and Aspira Scientific Announce Joint Venture to Commercialize New Fluorination Technologies 2
... FDA Clearance for a Phase II Trial of Its Long-Acting... -- NES-ZIONA, Israel, Aug. 24 ... ... ... ,; var first_result; // Results are keyed by longUrl, so we need to grab the first one. ...
... CHICAGO, Aug. 24 Advanced Life Sciences Holdings, ... a biopharmaceutical company engaged in the discovery, development and ... infection, oncology and respiratory diseases, today announced plans to ... once-daily antibiotic, Restanza™ (cethromycin) based on a new, high-profile ...
Cached Medicine Technology:PROLOR Biotech Receives FDA Clearance for a Phase II Trial of Its Long-Acting Human Growth Hormone in the U.S. 2PROLOR Biotech Receives FDA Clearance for a Phase II Trial of Its Long-Acting Human Growth Hormone in the U.S. 3PROLOR Biotech Receives FDA Clearance for a Phase II Trial of Its Long-Acting Human Growth Hormone in the U.S. 4PROLOR Biotech Receives FDA Clearance for a Phase II Trial of Its Long-Acting Human Growth Hormone in the U.S. 5PROLOR Biotech Receives FDA Clearance for a Phase II Trial of Its Long-Acting Human Growth Hormone in the U.S. 6PROLOR Biotech Receives FDA Clearance for a Phase II Trial of Its Long-Acting Human Growth Hormone in the U.S. 7PROLOR Biotech Receives FDA Clearance for a Phase II Trial of Its Long-Acting Human Growth Hormone in the U.S. 8Advanced Life Sciences Sees Funding Opportunity for Restanza in New HHS Medical Countermeasure Report 2Advanced Life Sciences Sees Funding Opportunity for Restanza in New HHS Medical Countermeasure Report 3Advanced Life Sciences Sees Funding Opportunity for Restanza in New HHS Medical Countermeasure Report 4Advanced Life Sciences Sees Funding Opportunity for Restanza in New HHS Medical Countermeasure Report 5
(Date:7/31/2014)... July 31, 2014 The Alaska ... hiring of new dentist Dr. Jonathan Oudin, DDS, who ... previously practiced in Barrow, Alaska, for three years. According ... Dentistry hired Dr. Oudin to help take on new ... Dentistry to continue growing and serving the greater Anchorage ...
(Date:7/31/2014)... THURSDAY, July 31, 2014 (HealthDay News) -- With the ... the West African Ebola outbreak has risen to 729, ... on Thursday issued a travel warning for,the region. ... travel to the affected countries -- Guinea, Liberia and ... is that Ebola is worsening in West Africa," CDC ...
(Date:7/31/2014)... Scientists have learned that recent fears of invasive lionfish ... efforts to control lionfish by fishing derbies and targeted ... invasion. And there,s a simple way to know for ... after it,s been cooked. , Pacific lionfish were first ... and have been gaining swiftly in number ever since. ...
(Date:7/31/2014)... 31, 2014 Insight Accelerator Labs member ... A round of investment for $4.6 million to fund ... collecting vital signs. The company joined Insight Accelerator ... fruition with the help of Insight development teams. ... for launching the Accelerator,” says Steve McPhilliamy, Executive Director ...
(Date:7/31/2014)... FL (PRWEB) July 31, 2014 Women ... to take charge of their financial future. The ... women, has opened registration for 6 upcoming Los Angeles ... women, for women, and with input from Kim Kiyosaki, ... and It’s Rising Time) who is passionate about women’s ...
Breaking Medicine News(10 mins):Health News:Dr. Jonathan Oudin to Join Alaska Center for Dentistry at Wasilla Location 2Health News:CDC Issues Travel Warning as West Africa Ebola Outbreak Worsens 2Health News:Invasive lionfish likely safe to eat after all 2Health News:Invasive lionfish likely safe to eat after all 3Health News:Insight Accelerator Labs Advances Member Toward Commercialization 2Health News:Insight Accelerator Labs Advances Member Toward Commercialization 3Health News:The Independent Woman to Offer Financial Workshops in the Los Angeles Area - Developed by Women for Women 2
... 31 /PRNewswire-FirstCall/ - MDS Inc. (TSX: MDS; NYSE:,MDZ), ... the global life,sciences markets, announced today that Stephen ... presenting at the Thomas Weisel Partners,Healthcare Conference in ... Standard Time. Interested parties may access the ...
... 31 Mylan Laboratories Inc.,(NYSE: MYL ) ("Mylan") ... for cash any and all of its outstanding 5.750% ... Notes due 2015 (CUSIP Nos.,628530AF4, 628530AC1) (collectively, the "Notes"). ... of a broader strategy to,establish its new global capital ...
... - QLT USA, Inc., a subsidiary,of QLT Inc. ... that the European,approval procedure for the Eligard(R) 45 ... formulation in 23 European countries,is expected to follow ... the individual countries. The 6-month formulation was launched ...
... UHW-West and 121RN, their, first ever wage scales ... Calif., Aug. 30 Caregivers at Providence St.,Joseph Medical ... -,West (UHW) and SEIU 121RN, reached a tentative agreement ... contract, which expires,Sept. 30, 2011, grants workers their first ...
... are likely culprits behind the increase, , , THURSDAY, Aug. ... in one sport early -- playing year-round, joining competitive ... programs -- believing they,ll put themselves on the fast ... sports career. , But for too many of these ...
... Over Health & Safety of,Seniors in Nursing Homes, ... death linked to an untreated oral infection, the,statewide organization ... oral health of seniors residing in nursing and,convalescent homes., ... it can be a matter of life and,death, especially ...
Cached Medicine News:Health News:Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Merck's Generic Pharmaceutical Business 2Health News:Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Merck's Generic Pharmaceutical Business 3Health News:Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Merck's Generic Pharmaceutical Business 4Health News:Eligard(R) six-month formulation successfully completes European approval procedure 2Health News:Eligard(R) six-month formulation successfully completes European approval procedure 3Health News:Providence St. Joseph Medical Center, Caregivers Reach Agreement on a Union Contract 2Health News:More Kids Are Suffering Sports Injuries 2Health News:More Kids Are Suffering Sports Injuries 3Health News:Oral Health a Matter of Life and Death for Seniors 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: